Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Immune checkpoint molecules" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immune checkpoint (ICP) molecules can amplify or dampen signals that lead to the modulation of specific immune activities. Under physiological conditions, immune checkpoints are essential to prevent autoimmune manifestations and to preserve self-tolerance.
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
PendingUS20170106065A1Viral antigen ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsCombined Modality TherapyMonoclonal antibody
The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with a monoclonal antibody against immune checkpoint molecule TIM-3.
Owner:BAVARIAN NORDIC AS
Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
PendingCN106456747AViral/bacteriophage medical ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAgonistTumor antigen
Owner:BAVARIAN NORDIC AS
Scoring method for quantifying TIME infiltration mode
PendingCN112164422AMicrobiological testing/measurementProteomicsHepatocellular carcinomaWhite blood cell
The invention discloses a scoring method for quantifying a TIME infiltration mode; the score for quantifying the TIME infiltration mode is called as a TIME index (TI), the TI is an excellent prognosisprediction index in hepatocellular carcinoma and pancreas carcinoma, and the performance of the TI in predicting immunotherapy response is superior to that of other 11 biomarkers. The results can strengthen the understanding of the immune microenvironment and guide more effective personalized treatment, and the TIME1 is characterized by immune cell depletion and cell proliferation and correspondsto immunodeficiency types; tIME2 is characterized by being in an immunosuppression state, and a potential immune escape mechanism of each phenotype is emphasized corresponding to immunosuppression: TIME1 is characterized by tumor infiltration leukocyte deficiency and tumor antigen presentation capability defects; the TIME2 has more immunosuppressive cells; the TIME3 is rich in immunosuppressive cytokines and immune checkpoint molecules.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Combination of, or bispecific binding molecule to, immune checkpoint molecule antagonist and rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefore
PendingCN111032085AInhibition toleranceImprove immunityHybrid immunoglobulinsAntibody ingredientsCancer preventionOncology
Disclosed are agents for treating or preventing cancers. More particularly, the present invention discloses the therapeutic combinations comprising antagonists of receptor of NF-KB (RANK) ligand and immune checkpoint molecules in methods and compositions for treating or inhibiting the development, progression or recurrence of cancers, including metastatic cancers.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
Attenuated virus vector system, application of attenuated virus vector system in preparation of anti-malignant tumor drugs and drug use method
InactiveCN110564767ALittle or no specific serum antibodiesRealize large-scale productionSsRNA viruses negative-senseUnknown materialsSingle-Chain AntibodiesMammal
The invention discloses an attenuated virus vector system, an application of the attenuated virus vector system in preparation of anti-malignant tumor drugs and a drug use method. The virus is RNA virus, its genetic material does not have integration capability in the mammalian cells, and the virus belongs to the field of rhabdoviridae and vesicular stomatitis viruses. The virus vector system structure gene chimeric coding molecule at least comprises an inhibitor specific to an immune checkpoint molecule, the attenuated virus vector system is a novel recombinant expression vector system for chimeric expression of a single-chain antibody aiming at an immune checkpoint, the replication can be specifically completed in tumor cells, and meanwhile, specific antibodies secreting molecules binding to the surfaces of the tumor cells can be expressed, the tumor antigen is released, the anti-tumor specific immune response of immune cells is activated at the same time, meanwhile, the secreted single-chain antibody breaks the immunosuppressive effect of the tumor microenvironment, the removal of CTL cells to tumor cells is promoted, a systematic specific anti-tumor immune memory reaction of anorganism is promoted, and the recurrence of tumors is controlled.
Owner:董春升
Method for treating infectious diseases by NK (natural killer) targeted immune checkpoints
ActiveCN109833480APrevent or treat infectious diseasesOrganic active ingredientsAntiviralsPharmaceutical drugImmune checkpoint molecules
Owner:INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI
Fully humanized single-domain antibody for human TIM-3 (T cell immunoglobulin and mucin-3) and applications
The invention belongs to the biotechnological field and particularly relates to a fully humanized single-domain antibody for human TIM-3 (T cell immunoglobulin and mucin-3), an antigen combing fragment of the antibody and applications of the antibody and the antigen combining fragment. The invention discloses the fully humanized single-domain antibody for the immune checkpoint molecule TIM-3 and the antigen combing fragment of the antibody. The single-domain antibody is mainly characterized by being determined by a CDR (complementarity-determining region) specific gene sequence existing in anantibody heavy chain gene variable region, and the effectively expressed antibody specifically combined with the TIM-3 is obtained from prokaryotic and eukaryotic cells. Different forms of geneticallyengineered antibodies can be modified and produced in prokaryotic and eukaryotic cells and any expression system by use of the CDR or partial or full gene of the body, and the antibody can be used for preparing preparations for clinical diagnosis or treatment of autoimmune diseases, chromic virus infection, tumor and other diseases.
Owner:FUDAN UNIV
Therapeutic agent for solid cancer
InactiveUS20170165364A1Suppress metastasisSuppress recurrenceOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenAnticarcinogen
Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.
Owner:IDAC THERANOSTICS +1
Method for predicting liver cancer feature type, electronic equipment and computer storage medium
ActiveCN114446393AImprove reliabilityStrong generalizationBiostatisticsProteomicsTumor SampleEngineering
The invention relates to a method for predicting liver cancer feature types, computing equipment and a storage medium. The method comprises the following steps: based on comparison result data about a tumor sample of a to-be-detected object, generating genome variation data about multiple predetermined genes of the tumor sample of the to-be-detected object; acquiring clinical data about the to-be-detected object; determining tumor mutation load information about the to-be-detected object; obtaining immune checkpoint molecular expression data of the to-be-detected object; generating input data of a prediction model at least based on the genome variation data, the clinical data, the tumor mutation load information and the immune checkpoint molecular expression data; and based on a prediction model trained by multiple samples, the prediction model is constructed based on a neural network model. According to the method, the reliability of predicting the liver cancer feature type can be improved, and good generalization of clinical application is achieved.
Owner:SHANGHAI ORIGIMED CO LTD +1
Antibodies for t-cell activation
ActiveUS20200407456A1Potent cross-linking dependent agonist activityExtraordinary activityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesCD137
Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.
Owner:AP BIOSCI INC
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
PendingUS20210030703A1Increase probabilityImprove the quality of lifeImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsPharmacometricsOncology
In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and / or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.
Owner:UNIVERSITÉ PARIS CITÉ +4
Method for evaluating blocking activity of immune checkpoint molecular blocking antibody by magnetic beads
The invention belongs to the field of immunological detection and particularly relates to a method for evaluating the blocking activity of an immune checkpoint molecular blocking antibody by magneticbeads. Magnetic beads with solid-phase anti-tag molecular antibodies and immune checkpoint molecular protein expressing label molecules (label I) subjected to solid-phase on the surfaces of the magnetic beads are used; the magnetic beads can be specifically bound with a ligand of an immune checkpoint molecule with another label molecule (label II), and then a label II specific binding antibody labeled by a biologic substance (fluorescent or visible light) is used for quantitatively detecting the immune checkpoint molecular protein / ligand molecular protein compound on the surface of the magnetic bead. When the blocking antibody of the immune checkpoint molecule, the magnetic beads with the immune checkpoint molecule protein in the solid phase and the ligand protein coexist, the blocking activity of the antibody is inversely proportional to the final luminous intensity of the magnetic beads, so that quantitative analysis on the blocking activity of the antibody is realized through lightintensity detection. The magnetic bead method is simple to operate, quick in reaction, economical and time-saving.
Owner:SHANXI UNIV
Application of GnT-II gene down-regulated expression as liver cancer prognostic marker
The invention discloses application of GnT-II gene down-regulation expression as a liver cancer prognosis marker. A CRISRP human whole genome coding gene knockout library is used for screening a coding gene GNT-II for regulating expression of an inhibitory immune checkpoint molecule CD155, and it is found that expression of GNT-II in tumor tissue of a liver cancer patient is positively correlatedwith expression of CD155; and furthermore, the expression of the GNT-II is obviously related to the prognosis of the liver cancer patient, that is, the higher the expression of the GNT-II in the earlymale liver cancer patient is, the poorer the prognosis of the patient is. Therefore, the GNT-II has a certain potential application value as a prognosis index in liver cancer.
Owner:PEOPLES HOSPITAL PEKING UNIV
Modified N-810 and Methods Therefor
Compositions and methods for multi-specific protein complexes comprising an interleukin-15 (IL-15) domain comprising an N72D mutation (IL-15N72D), a IL-15 receptor alpha sushi-binding domain (IL-15RαSu), an immunoglobulin Fc domain, and a mutated transforming growth factor-beta receptor type 2 (TGFβRII) domain, wherein the mutated TGFβRII domain has a N->Q mutation in positions 47, 71, and 131 respectively. The IL-15RαSu domain, the Fc domain, and the mutated TGFβRII domain are sequentially linked by amide bonds. Preferably, contemplated complexes further include a binding domain that specifically binds to a disease antigen, immune checkpoint molecule, or immune signaling molecule.
Owner:NANTBIO INC
Co-expression of recombinant immune checkpoint receptor and immune checkpoint inhibiting molecules and application
InactiveCN107586341AImproved targeted killing effectEnhance specific killing effectMammal material medical ingredientsViruses/bacteriophagesLymphocyteImmune Stimulation
The invention puts forward a transgenic lymphocyte, a construct and a cancer treatment composition. A cell immune checkpoint of the transgenic lymphocyte is silenced and can be used for expression ofa recombinant receptor, and the recombinant receptor includes: a cell immune checkpoint molecule fragment; an immunostimulation molecule fragment; and a T cell receptor zeta chain. The transgenic lymphocyte has the characteristic of resistance to tumor cell mediated immunosuppression, and has significantly strengthened tumor cell killing ability.
Owner:LIFESEQ LTDRP
Novel immunomodulatory therapeutic strategies targeting tumors in cancer
InactiveUS20180134771A1Increase delayEasy to controlImmunoglobulins against animals/humansAntibody ingredientsImmuno modulationWilms' tumor
The present invention discloses a method of treating, preventing or ameliorating tumor growth by immune response modulation via targeting ABCB5 and an immune checkpoint molecule related pathways using various therapeutic agents such as antibody or small molecule. The present invention also provides use of an ABCB5 inhibitor and an immune checkpoint inhibitor(s) for enhancing, increasing, promoting, expressing, modulating desirable immune response for prevention and treatment of tumors.
Owner:BIOXCEL LLC
Combination of an agonist anti-PD-1 antibody with a GnRH agonist or antagonist to treat cancer
ActiveCN111727060APeptide/protein ingredientsSkin cancer vaccineAntiendomysial antibodiesProgrammed death
Owner:DEBIOPHARM INTERNATIONAL SA
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
TIM-3 single-domain antibody and application thereof
PendingCN110938146AInhibition of antitumor activityImprove anti-tumor activityHybrid immunoglobulinsAntibody mimetics/scaffoldsDiseaseComplementarity determining region
The present invention provides a single-domain antibody or an antigen-binding fragment thereof capable of specifically binding to an immune checkpoint molecule TIM-3, a polynucleotide encoding the single-domain antibody or antigen-binding fragment, and uses based on the single-domain antibody or the antigen-binding fragment, and the polynucleotide. The provided single-domain antibody or the antigen-binding fragment thereof is composed of a frame region of an antibody heavy chain variable region (VH) and an antigen-binding complementarity determining region (CDR). The frame region and the CDR region can be combined according to different ways. The provided single-domain antibody or the antigen-binding fragment can block binding of Galectin-9 and TIM-3 and increase activity of T cells. The provided single-domain antibody or the antigen-binding fragment thereof can be used for diagnosis, treatment, and adjuvant treatment of diseases of tumors, immune diseases, infectious diseases, etc., and can also be used to detect presence of TIM-3 protein and content thereof in biological samples.
Owner:HUAZHONG AGRI UNIV
Therapeutic agent for solid cancer
InactiveUS20190125867A1Suppress metastasisSuppress recurrenceOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenLymphatic Spread
Owner:IDAC THERANOSTICS
Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient
ActiveUS10746726B2Less variationImprove homogeneityMicrobiological testing/measurementDisease diagnosisAnticarcinogenAntiendomysial antibodies
Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and / or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.
Owner:IDAC THERANOSTICS +1
Detection of immune checkpoint molecules by deglycosylation
PendingUS20210156866A1Improve the level ofImprove responseHydrolasesImmunoglobulins against cell receptors/antigens/surface-determinantsImmune checkpoint moleculesMolecular biology
Provided herein are methods of detecting glycosylated proteins, such as immune checkpoint proteins. Further provided are methods of treating cancer, such as by administering immune checkpoint inhibitors.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Co-expression of secretory anti-immune checkpoint antibody, intracellular immune checkpoint inhibiting molecule and tEGFR molecule and application thereof
InactiveCN109750066AAchieve and facilitate specific killingImprove securityAntibody ingredientsViruses/bacteriophagesEffect functionImmune checkpoint molecules
The invention provides an expression vector, a lentivirus, a transgenic cell, a secretory antibody and a therapeutic composition for treating cancer. The expression vector carries the following nucleic acid molecules: (a) a first nucleic acid molecule, which is used for encoding a secretory immune checkpoint inhibiting molecule fragment; (b) a second nucleic acid molecule, which is used for silencing an intracellular immune checkpoint and optionally further carrying a third nucleic acid molecule, wherein the third nucleic acid molecule is used for encoding a non-functional EGFR. The expressionvector of the embodiment of the invention is introduced into receptor cells, a secretory anti-immune checkpoint antibody is efficiently expressed in the receptor cells and secreted outside the cells,meanwhile, the immune checkpoint molecules of the receptor cells are specifically silenced, and an immune escape mechanism mediated by the immune checkpoint is repressed. When the expression vector of the embodiment of the invention is introduced into the receptor cells, such as lymphocytes, the proliferation capacity and the effect function of the lymphocytes are enhanced, and the specific killing of tumor cells is stronger and more effective.
Owner:ILIFESEQ LTD CORP
Application of RPS3A molecule in prediction of immune cell infiltration and immune checkpoint molecular expression level in tumors and predicting model
ActiveCN111983231AHelps personalize treatmentImprove poor prognosisHealth-index calculationBiological material analysisParanasal Sinus CarcinomaHepatocellular carcinoma
The invention provides an application of an RPS3A molecule in prediction of immune cell infiltration and immune checkpoint molecular expression level in tumors and a prediction model. According to theinvention, the expression level of RPS3A in postoperative tumor tissues of a hepatocellular carcinoma patient is detected; in clinical practice, the RPS3A can be used as a molecular marker to reflectthe infiltration level of immune cells in tumors and the molecular expression condition of immune checkpoints and guide the immunotherapy management of liver cancer patients, so that the immunological characteristics and prognosis risk of hepatocellular carcinoma can be evaluated, the formulation of a liver cancer individualized treatment scheme can be promoted, and relatively high guiding significance is achieved; meanwhile, the Nomogram prognosis prediction model is constructed on the basis of RPS3A molecules, compared with traditional TNM and BCLC stages, better prediction efficiency and accuracy are achieved, liver cancer patients are enabled to obtain more clinical net income, and the RPS3A molecule can be applied to clinically and accurately judging the postoperative survival time of hepatocellular carcinoma patients.
Owner:JUSBIO SCI SHANGHAI CO LTD
Methods for reducing side effects of immunotherapy
PendingUS20200113829A1Toxic effectsEliminate side effectsPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesSide effect
This invention provides methods to overcome the current limitations of immune checkpoint immunotherapy to provide more effective methods of treating cancer. In embodiments this invention provides a means of using of p53 gene therapy to augment immune checkpoint inhibition by combining antibodies targeting immune checkpoint molecules with SGT-53, a nanomedicine carrying a plasmid encoding human wild-type p53. This invention provides means of increasing tumor immunogenicity, enhancing both innate and adaptive immune responses, and reducing tumor-induced immunosuppression, sensitizing otherwise refractory tumors to anti-immune checkpoint antibodies. In other embodiments this invention also unexpectedly reduces immune-related toxicities that are seen with immunotherapies.
Owner:SYNERGENE THERAPEUTICS +1
Inhibitor against expression of immune checkpoint molecule
PendingUS20220340665A1Inhibit and ameliorate exacerbationEnhancer of immunotherapyImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsBiochemistryImmune checkpoint molecules
The present invention provides a novel use of a compound having a plasminogen activator inhibitor-1 (PAI-1) inhibitory effect. Specifically, a compound having a PAI-1 inhibitory effect is used as an intranostimulator, an immune checkpoint inhibitor, an inhibitor for exacerbation of tumor cells caused by PD-L1, or an enhancer of immunotherapy for tumors, based on the inhibitory effect of the compound on expression induction of immune checkpoint molecules.
Owner:RENASCI
Modified N-810 and methods thereof
Owner:NANTBIOSCI
Anti-immune checkpoint PD-L1 and PD-L2 tumor vaccines
ActiveCN107286244BPeptide/protein ingredientsSerum immunoglobulinsAntiendomysial antibodiesImmune checkpoint molecules
Owner:BEIJING POMONA BIOLOGICAL TECH CO LTD
A bispecific antibody for multiple myeloma and its application
ActiveCN112159476BEnhanced lethalityHybrid immunoglobulinsAntibody ingredientsProtein targetCell recruitment
Owner:CHINA PHARM UNIV
Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
PendingUS20210369776A1Reduce functionReduce expressionAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsTumor antigenT cell
The present disclosure is directed towards genetically engineered TCR-T cells to recognize tumor antigens and simultaneously secrete a binding protein that blocks an immune checkpoint molecule and TGF-beta. These engineered T cells demonstrate stronger antitumor response and reduced T cell exhaustion. The present disclosure provides immunotherapy against HPV- or EBV-positive cancers, among others.
Owner:GUANGDONG TCRCURE BIOPHARMA TECHNOLOGY CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com